Home › Lung Cancer › Washington › Kennewick
Lung Cancer clinical trials in Kennewick, WA
4 studies for Lung Cancer are looking for participants at sites in and around Kennewick (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Kadlec Clinic Hematology and Oncology, Kennewick
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Kadlec Clinic Hematology and Oncology, Kennewick
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecruitingPhase 3
- Kadlec Clinic Hematology and Oncology, Kennewick
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Kadlec Clinic Hematology and Oncology, Kennewick
About Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
More about Lung Cancer on MedlinePlus
Lung Cancer trials in other cities
- Houston, TX78 studies
- Boston, MA63 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Chicago, IL43 studies
- Arlington, VA42 studies
- Washington, DC41 studies
- Baltimore, MD41 studies
- Nashville, TN39 studies
- St. Louis, MO37 studies
- Columbus, OH36 studies
- Philadelphia, PA36 studies
Other studies in Kennewick
- Prostate Cancer5 studies
- Colorectal Cancer5 studies
- Melanoma4 studies
- Breast Cancer4 studies
- Colon Cancer3 studies
- Non-Small Cell Lung Cancer3 studies
- Metastatic Cancer3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.